Carregant...
Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer
Despite decades of research, pancreatic ductal adenocarcinoma (PDAC) is still one of the most lethal malignant diseases with a devastating 5‑year overall survival of only 4–5%. Indeed, long-term survival was not affected by the introduction of new systemic cytotoxic chemotherapies which remain the k...
Guardat en:
| Publicat a: | Memo |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Vienna
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5605578/ https://ncbi.nlm.nih.gov/pubmed/28989542 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12254-017-0352-2 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|